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Ephraim J. Fuchs,1 Xiao-jun Huang,2 Jeffrey S. Miller3Partially HLA-mismatched related, or HLA-haploidentical, donor stem cell transplantation (SCT) is a feasible
therapeutic option for advanced hematologic malignancies patients who lack an HLA-matched related or un-
related donor. Advances in conditioning regimens, graft manipulation, and pharmacologic prophylaxis of
graft-versus-host disease (GVHD) have reduced the risk of fatal graft failure and severe GVHD, two of
the most serious complications of traversing the HLA barrier. Clinical observations reveal a potential role
for natural killer (NK) cell alloreactivity in reducing the risk of relapse of acute myeloid leukemia after
HLA-haploidentical SCT. NK cell infusions attempt to harness the graft-versus-leukemia effect without pro-
ducing GVHD. The availability of multiple potential HLA-haploidentical related donors for most patients
opens the possibility of optimizing transplantation outcome through intelligent donor selection.
Biol Blood Marrow Transplant 16: S57-S63 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Stem cell transplantation, Adoptive immunotherapy, Natural killer cells, Graft-versus-host
disease, Human leukocyte antigens, Transplantation conditioningINTRODUCTION
Donor availability is one of the major obstacles to
the success of allogeneic hematopoietic stem cell trans-
plantation (HSCT) for the treatment of hematologic
malignancies or nonmalignant hematologic disorders.
Because of historically superior outcomes of human
leukocyte antigen (HLA)-matched compared to
partially HLA-mismatched HSCT [1,2], an HLA-
matched sibling or unrelated donor (URD) is the
preferred source of stem cells for transplantation.
However, an HLA-matched donor can be identified
for only 50% to 60% of patients referred for HSCT,
lower still for patients in ethnic minorities. The ability
to cross the HLA boundary safely would increase the1Division of Hematologic Malignancies, Sidney Kimmel
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tients referred for allogeneic HSCT.
There are two potential sources of grafts for pa-
tients lacking HLA-matched donors: (1) unrelated
umbilical cord blood (UCB), and (2) partially HLA-
mismatched, or HLA-haploidentical, related donors.
Results of UCB transplantation in children are en-
couraging [3], and transplantation of 2 UCB units
generates cell doses that are sufficient for engraft-
ment in adults [4,5]. The initial studies of HLA-hap-
loidentical HSCT employed lethal conditioning,
infusion of T cell-replete marrow grafts, and graft-
versus-host disease (GVHD) prophylaxis with metho-
trexate (MTX), with or without cyclosporine (CsA)
[6]. These transplants were complicated by excessive
bidirectional alloreactivity resulting in high rates of
graft failure [7], severe GVHD, and nonrelapse mor-
tality (NRM) [8]. Consequently, event-free survival
(EFS) was poor, especially when donors and recipi-
ents were mismatched for 2 or more HLA antigens
[1,8]. Results of HLA-haploidentical HSCT have im-
proved significantly over the past decade owing to the
development of highly immunosuppressive yet non-
myeloablative (NMA) conditioning, novel graft ma-
nipulation, and improved prophylaxis of GVHD.
Further, HLA-haploidentical HSCT harnesses the
potential of natural killer (NK) cell alloreactivity to
kill tumor cells and reduce the risk of posttransplan-
tation relapse. These recent developments are the
subject of this review.S57
Figure 1. Treatment schema for nonmyeloablative conditioning and
HLA-haploidentical bone marrow transplantation. From ref. 11.
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Graft failure is a major complication of HLA-
haploidentical HSCT [6,9] and is usually a fatal event
after myeloablative (MA) conditioning. Truly NMA
conditioning offers the safeguard of reconstitution of
autologous hematopoiesis in the event of graft failure.
Most NMA conditioning regimens incorporate the
highly immunosuppressive drug fludabarine (Flu).
Studies from Tuebingen, Germany, and from Duke
University in the United States have combined Flu-
based conditioning with in vivo T cell depletion
(TCD) using OKT3 [10] or CAMPATH [11], respec-
tively, to enable the engraftment of HLA-haploidenti-
cal stem cells. These regimens were associated with
acceptable nonhematologic toxicities and sustained en-
graftment of donor cells in patients up to the age of 66
years. Overall survival (OS) at 1 year after transplanta-
tion ranged from 31% to 37% [11,12], establishing
the feasibility of HLA-haploidentical HSCT after
NMA conditioning.
The groups at Johns Hopkins in Baltimore and the
Fred Hutchinson Cancer Research Center in Seattle
have been pioneering the use of high-dose, posttrans-
plantation cyclophosphamide (Cy) to achieve the
selective depletion of alloreactive cells after NMA
conditioning and HLA-haploidentical HSCT. In an
early report, 68 patients with poor-risk hematologic
malignancies were conditioned with Flu, Cy, and
2 Gy total body irradiation (TBI) prior to receiving T
cell-replete bonemarrow (BM) fromHLA-haploident-
ical, first-degree relatives (Figure 1) [13]. Donors and
recipients were mismatched at a median of 4 HLA
alleles. GVHD prophylaxis comprised Cy 50 mg/kg
i.v. on day 3 (n5 28) or on days 3 and 4 (n5 40) after
transplantation, followed by tacrolimus and mycophe-
nolate mofetil (MMF), each beginning on day 5. Graft
failure occurred in 9 patients (13%) butwas fatal in only
1.Grades II-IV and III-IV acuteGVHD (aGVHD)oc-
curred in 34% and 6% of patients, respectively, and
chronic GVHD (cGVHD) developed in 15% of
patients. The cumulative incidences of relapse and
NRM at 1 year after transplantation were 15% and
51%, respectively, and OS and EFS at 2 years after
transplantation were 36% and 26%. Only 6 patients
died of infection (n5 4) orGVHD (n5 2). In this early
report, patients with lymphoid diseases had a superior
EFS compared to patients receiving HSCT for mye-
logenous diseases (P5 .02).
A subsequent report retrospectively compared the
outcomes of Hodgkin lymphoma (HL) patients
treated with NMA conditioning and grafts from
HLA-matched related (n5 38), URD (n5 24), or
HLA-haploidentical related (n5 28) donors [14]. Re-
cipients of HLA-haploidentical grafts were condi-
tioned as in Figure 1. Patients had received a medianof 5 prior regimens, including autologous HSCT in
92%. With a median follow-up of 25 months, 2-year
OS, EFS, and incidences of relapsed/progressive dis-
ease were 53%, 23%, and 56% (HLA-matched re-
lated), 58%, 29%, and 63% (URD), and 58%, 51%,
and 40% (HLA-haploidentical related), respectively.
NRM was significantly lower for HLA-haploidentical
related recipients compared to HLA-matched related
recipients (P5 .02). There were also significantly de-
creased risks of relapse for HLA-haploidentical related
recipients compared to HLA-matched related
(P5 .01) and URD (P5 .03) recipients. In a recent re-
port from the Center for International Blood andMar-
row Transplant Research (CIBMTR), HL patients
receiving reduced intensity, unrelated donor HSCT
had a 2-year OS and EFS of 37% and 20%, respec-
tively [15]. HLA-haploidentical HSCT may therefore
be uniquely effective for patients with relapsed or re-
fractory HL.
We have recently analyzed, retrospectively, the ef-
fect of HLA mismatching on the outcome of 185 he-
matologic malignancies patients treated with NMA,
HLA-haploidentical SCT and posttransplantation
Cy [16]. The cumulative incidences of grade II-IV
aGVHD and cGVHD were 31% and 15%, respec-
tively. The cumulative incidences of NRM and relapse
or progression at 1 year were 15% and 50%, respec-
tively. Actuarial EFS at 1 year was 35%. Increasing de-
grees of HLA mismatch at either class I or class II loci
had no significant effect on the cumulative incidence of
aGVHD or cGVHD or NRM. In contrast, the pres-
ence of an HLA-DRB1 antigen mismatch in the
GVH direction was associated with a significantly
lower cumulative incidence of relapse (Figure 2A;
P5 .04) and improved EFS (Figure 2C; P5 .009),
whereas HLA-DQB1 antigen mismatch status had
no effect. Additionally, the presence of 2 or more class
I allele mismatches (composite of HLA-A, -B, and
-Cw) in either direction was associated with a signifi-
cantly lower cumulative incidence of relapse
(Figure 2B; P5 .045 for GVH direction, P5 .01 for
HVG direction) and improved EFS (Figure 2D;
P5 .07 for GVH direction, P5 .001 for HVG direc-
tion). Although the analysis was limited by its retro-
spective nature and the small numbers of pairs with 2
or fewer HLA antigenmismatches (n5 26), the results
Figure 2. Effect of HLA-DRB1 antigen mismatch (a,c) or HLAClass I allele mismatches (b,d) in the GVH direction on relapse, NRM (a,b), and EFS (c,d)
after nonmyeloablative, HLA-haploidentical bone marrow transplantation with high-dose, posttransplantation cyclophosphamide.
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associated with improved outcomes after NMA,
HLA-haploidentical HSCT with high-dose, post-
transplantation Cy.
Previous studies of MA, HLA-haploidentical
HSCT have shown that increasing HLA disparity
was associated with a reduced incidence of relapse,
but an inferior EFS because of increased GVHD and
NRM [8,17]. In contrast, our study of NMA, HLA-
haploidentical HSCT with posttransplantation Cy
showed that increasing HLA disparity was associated
with a reduced risk of relapse with no effect on
NRM, resulting in an improved EFS. What accounts
for the difference? Although conceding the pitfalls of
retrospective analyses, we raise the possibility that
posttransplantation Cy differentially affects the popu-
lations of cells mediating GVHD versus those produc-
ing graft-versus-leukemia (GVL) effects. Further
clinical and laboratory studies will be required to un-
derstand the effects of high-dose, posttransplantation
Cy on host tolerance and antitumor immunity.ATG  2.5mg/kg(r)
-3
-1
-4
MeCCNU  250 mg/m2
-2
01 BMSC
02 PBSC
Figure 3. The myeloablative conditioning regimen for HLA-haploi-
dentical HSCT at Peking University. Ara-C: cytosine arabinoside; Bu:
busulfan; Cy: cyclophosphamide; MeCCNU: simustine; ATG: antithymo-
cyte globulin.HLA-Haploidentical HSCTafter MA
Conditioning
As mentioned previously, the initial trials of HLA-
haploidentical BM transplantation (BMT) for leuke-
mia used lethal conditioning and T cell-replete grafts
and were complicated by high rates of severe GVHD
and NRM, and 5-year EFS among recipients of grafts
mismatched for 2 to 3 HLA loci was approximately
10% [8]. Although T reduced the risk of GVHD after
HLA-haploidentical HSCT, it increased the risk of
graft failure and did not improve leukemia-freesurvival (LFS) [18]. Investigators in Perugia, Italy,
achieved low rates of graft failure and GVHD by con-
ditioning patients intensively and transplanting them
with rigorously T cell-depleted grafts containing
‘‘megadoses’’ of CD341 HSC [19]. EFS (6 standard
deviation) rate was 48% 6 8% and 46% 6 10%, re-
spectively, for 42 acute myelogenous leukemia
S60 Biol Blood Marrow Transplant 16:S57-S63, 2010E. J. Fuchs et al.(AML) and 24 acute lymphoblastic leukemia (ALL)
patients receiving transplantation in remission [20].
These studies also established a potential role for
donor NK cells in mediating GVL effects after
TCD, HLA-haploidentical BMT for AML, but not
ALL [21].
Peking University researchers developed a novel
approach to HLA-mismatched/haploidentical trans-
plantation without in vitro TCD. This approach,
shown in Figure 3, was first reported by Huang et al.
[22] in a study of 58 patients undergoing HLA-
mismatched/haploidentical HSCT. Since this initial
report, 831 additional patients have received HLA-
haploidentical SCTs at the Peking University Institute
of Hematology.
Engraftment
Huang et al. [23] reported 171 patients, including
86 with high-risk disease, receiving grafts from
HLA-mismatched/haploidentical family donors. All
patients achieved hematopoietic recovery after trans-
plantation. The median time for myeloid engraftment
was 12 days (range: 9-26 days) and median time to
platelet recovery was 15 days (range: 8-151 days).
There was no significant association between the ex-
tent ofHLA disparity and the time tomyeloid or plate-
let recovery. On multivariate analysis, a low number of
CD341 cells (\2.19 106/kg) in the graft, and ad-
vanced disease stage were independently associated
with an increased risk of platelet nonengraftment
[24]. Among children who received HLA-haploident-
ical grafts, only the dose of infused CD341 cells/kg of
recipient weight was significantly associated with an
increased risk of platelet engraftment.
GVHD
Our results suggest that the incidences of grade
III-IV aGVHD and extensive cGVHD were accept-
able in patients after unmanipulated HLA-mis-
matched/haploidentical transplantation, although the
T cell dose in grafts was more than 108/kg. At 100
days after transplantation, the cumulative incidence
was 55.0% for grade II-IV aGVHD, and 23.1% for
grade III-IV aGVHD. The incidence of cGVHD
was 44.67%, with 21.3% for limited and 23.3% for ex-
tensive, respectively [23]. We further reported 42 chil-
dren below 14 years of age with hematologic
malignancies treated with HLA-haploidentical HSCT
[25]. The cumulative incidence of aGVHD of grade
II-IV was 57.2%, and that of grade III-IV was 13.8%.
The cumulative incidence of cGVHD was 56.7% for
total and 29.5% for extensive. Apparently, the inci-
dence of grade III-IV aGVHD in pediatric patients
was lower than that of adult patients. In contrast to pre-
viously published data, there was no significant associ-
ation of HLA disparity with the incidence or severity of
aGVHD or cGVHD in this protocol.These findings may be related to (1) T cell hypo-
responsiveness maintained after in vitro mixture of fil-
grastim (G-CSF)-mobilized peripheral blood (G-PB)
and filgrastim-mobilized bone marrow (G-BM) in dif-
ferent proportions [26,27]; (2) the use of antithymo-
cyte globulin (ATG) before transplantation, which
may induce depletion of infused donor T lymphocytes
in vivo and thus lower the incidence of GVHD; (3)
a possible effect of the combination of CsAMTX,
and MMF as postgrafting immunosuppression; (4)
the application of granulocyte-colony stimulating fac-
tor (G-CSF) day 5 posttransplant, which may further
regulate T cell function; or (5) the immunomodulatory
effect of mesenchymal stem cells (MSCs)/mesenchy-
mal (stroma) progenitor cells (MPCs) from the G-
CSF mobilized BM and peripheral blood stem cell
(PBSC) grafts, respectively.
Factors correlating the high incidence of aGVHD
are killer cell immunoglobulin-like receptor (KIR) li-
gand mismatch and a higher dose of CD56bright NK
cells (41.9 106/kg) in the allografts, whereas a higher
CD56dim/CD56bright NK cell ratio (more than 8.0) in
allografts was correlated with a decreased risk of III-IV
aGVHD after unmanipulated HLA-mismatched/hap-
loidentical transplantation.Relapse and management
We studied the incidence and management of
relapsed malignancy in 250 recipients of HLA-hap-
loidentical transplants at Peking University [28].
The 3-year probabilities of relapse in the stan-
dard-risk group were 11.9% for a AML and
24.3% for ALL, and in the high-risk group were
20.2% for AML and 48.5% for ALL. Advanced dis-
ease status, a higher CD4/CD8 ratio in G-BM [29],
and delayed lymphocyte recovery at day 30 post-
transplantation correlated with an increased relapse
rate. Conversely, a higher CD56dim/CD56bright
NK cell ratio (more than 8.0) was correlated with
a decreased rate of relapse after haploidentical
transplantation without in vitro TCD.
Modified donor lymphocyte infusions (DLI) was
used to treat relapse of patients after unmanipulated
HLA-mismatched/haploidentical transplantation [30].
Twenty patients who underwent T cell-depleted,
HLA-haploidentical HSCT between April 1, 2002
and May 1, 2005 were included in this study. After
DLI, 11 patients received CsA (blood concentration
of 150-250 ng/mL for 2-4 weeks) or a low dose of
MTX (10 mg once per week for 2-4 weeks) to pre-
vent GVHD, and 9 patients received no GVHD pro-
phylaxis. The incidence of grade III-IV aGVHD was
significantly lower in patients with GVHD prophy-
laxis than those without (9.1% versus 55.6%,
P5 .013). Fifteen patients achieved complete remis-
sion (CR) at a median of 289 (40-1388) days after
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40%.
Treatment-related mortality and survival
In a recent report, 250 acute leukemia (AL) pa-
tients received allografts from related donors [28].
The NRM at day 100 after transplantation in the stan-
dard- and high-risk groups was 6.8% and 5.9% for
AML and 6.9% and 25.9% for ALL, respectively.
An improved LFS after unmanipulated HLA-
haploidentical blood and marrow transplantation
correlated closely with early disease status, higher
numbers of CD56bright cells reconstituted day 14 post-
transplant, lower CD4/CD8 in G-BM, a short time
from diagnosis to transplant (#450 days) for chronic
myelogenous leukemia (CML) patients and higher ab-
solute lymphocyte counts (ALC; .300/mL) day 30
posttransplant. In a large cohort of AL patients, the
3-year probabilities of LFS for standard-risk and
high-risk patients were 70.7% and 55.9%, respec-
tively, for patients with AML, and 59.7% and
24.8%, respectively, for patients with ALL [28].
With respect to CML patients, the probability of 1-
year and 4-year LFS was 76.5% and 74.5% for patients
in first chronic phase (CP), 85.7% and 85.7% for CP2/
CR2 patients, 80% and 66.7% for patients in acceler-
ated phase (AP), and 53.8% and 53.8% for patients in
blast crisis (BC).
HLA-haploidentical HSCT: current status
The most important development in HLA-haploi-
dentical HSCT over the past decade has been the dra-
matic reduction in treatment-related morbidity and
treatment-related mortality (TRM). Highly immuno-
suppressive conditioning regimens now permit the
transplantation of TCD grafts, resulting in reliable
donor cell engraftment without severeGVHD.As a re-
sult, the mortality associated withHLA-haploidentical
HSCT now approaches that of HLA-matched HSCT
[31], making partially mismatched related donor trans-
plantation a viable treatment option for patients lack-
ing an HLA-matched donor. Going forward, there is
a need to decrease the risk of posttransplant infections
by improving immune reconstitution, to harness both
T cell and NK cell alloreactivity for improved antitu-
mor effects without GVHD, and to define the relative
roles of HLA-haploidentical related donor versus un-
related umbilical cord blood SCT for various hemato-
logic malignancies.Biology of NK Cell Alloreactivity
Development of NK cell self-tolerance
ThemechanismbywhichNKcells acquire self-tol-
erance and alloreactivity has been referred to asNKcell
education or licensing. This is one of the most widelydebated topics in NK cell biology over the past several
years. Several models have been proposed to explain
the integration of inhibitory receptor expression with
the acquisition of effector function. These concepts
differ in their implied mechanisms and whether the
process is one of activation or loss of function [32,33].
What is agreed upon between these and other models
is that human NK cells lacking inhibitory receptors
are hyporesponsive [34,35]. Therefore, rather than be-
ing autoreactive, they are self-tolerant. Although the
exact mechanism remains unknown, self-tolerance
may be the result of coordinated developmental path-
ways wherebymatureNK cell function is synchronized
with the acquisition of self-inhibitory receptors.
Therapeutic efficacy of NK cells is primarily
controlled by KIR interactions
The 2 main strategies to harness the therapeutic
power of alloreactive NK cells are: (1) HSCT [21]
and (2) adoptive transfer of NK cells [36]. This litera-
ture is based on studies from the Perugia group who
first proposed the KIR-ligand incompatibility model,
which predicts that donor-derived NK cells will be al-
loreactive when recipients lack C2, C1, or Bw4 alleles
that are present in the donor. Many groups, including
our own [37-39], have tested the clinical efficacy of se-
lecting donors for NK cell therapy or transplantation
based on their predicted alloreactivity against the
host using one of several models. The potential bene-
fits include: (1) decreased GVHD as host dendritic
cells are killed by donor NK cells, (2) better antitumor
activity via direct cytotoxicity, (3) improved engraft-
ment mediated by NK cell release of hematopoietic
cytokines, and (4) enhanced immune reconstitution.
Additional clinical trials have supported the finding
that KIR ligand mismatch is associated with favorable
clinical outcomes in myelogenous malignancies [40].
However, other studies looking at outcomes after
KIR ligand mismatched, T cell-replete transplants
did not find the same effect, perhaps because T cells
in the graft interfere with NK cell development and
KIR reconstitution after allogeneic donor transplant
as we have shown [41]. Taken together, these results
suggest that NK cells play a role in allogeneic trans-
plant and cancer therapy; however, the complexities
of the KIR system and the presence of other functional
receptors on NK cells may explain some of the confu-
sion in interpreting published studies.
Adoptive transfer of allogeneic NK Cells
in combination with a nonmyeloablative
haploidentical transplantation
We have shown that adoptive transfer of haploi-
dentical NK cells can induce remissions in 27% of pa-
tients with refractory or relapsed AML [6]. The
remissions induced by adoptive NK cell transfer
were not durable. We hypothesized that this may be
S62 Biol Blood Marrow Transplant 16:S57-S63, 2010E. J. Fuchs et al.in part related to the lack of in vivo expansion of NK
cells on all patients. Because lymphocyte homeostasis
is determined by factors resulting from lymphodeple-
tion, we increased our preparative regimen and added
a CD341 stem cell infusion to create an NMA haploi-
dentical transplantation protocol. Radiation (200 cGy
twice a day on day213) was added to a preparative reg-
imen used in nontransplant patients that included Flu
25 mg/m2 5 (day 218 through day 214) and Cy
60 mg/kg 2 (days216 and215). The NK cell prod-
uct was activated with 1000 U/mL IL-2 and infused on
day 212 followed by 6 doses subcutaneous IL-2 (10
million units) given every other day to promote in
vivo NK cell expansion. The mean NK cell dose was
1.85 107 cells/kg. A CD34-selected peripheral blood
graft from the same donor was given with Thymoglo-
bulin 3 mg/kg days 0,11 and12 as the only additional
immunosuppression. In the 13 patients a significantly
higher rate of NK cell expansion (75% [9/12 evalu-
able]; mean 6076 184 NK cells/mL) was achieved
compared to the adoptive NK cell transfer regimen,
which did not include radiation. This adoptive NK
cell plus allograft protocol led to 66% of relapsed or
refractory AML patients (8/12 evaluable) clearing leu-
kemia by day 21. Patients who did not clear leukemia
(N5 4) did not engraft. All others (N5 6) engrafted
promptly at a median 17 days [range: 11-31]). None
developed GVHD, but infectious complications were
common, not unexpected in a high-risk cohort where
subjects typically had prolonged neutropenia prior to
transplantation. In summary, in patients with refrac-
tory AML, addition of haploidentical NK cells to an
NMA haploidentical transplantation yields NK cell
expansion in a majority of patients, achievement of
CR, and quick engraftment without GVHD. This is
a promising platform upon which to add other strate-
gies aimed at improving disease-free survival (DFS) in
patients with refractory AML. Additional strategies to
sensitize NK cells to leukemia, to target leukemic stem
cells, to improve in vivo expansion, to interrupt inhib-
itory receptor interactions with class I major histo-
compatibility complex (MHC) and to pick donors
are among future strategies to improve this therapy.KIR genotyping: implications for donor selection
The importance of KIR in determining clinical
outcome after HCT remains controversial. We geno-
typed donors and recipients from 209 HLA-matched
and 239 mismatched T-replete URD transplantations
for AML [42]. Three-year OS was significantly higher
after transplantation from aKIRB/x donor (31% [95%
confidence interval [CI]: 26-36] versus 20% [95% CI:
13-27]; P 5 .007). Multivariate analysis demonstrated
a 30% improvement in the relative risk of relapse-free
survival (RFS) with B/x donors compared with A/A
donors (relative risk [RR]: 0.70 [95% CI: 0.55-0.88];P5 .002). This demonstrates that unrelated donors
with KIR B haplotypes confer significant survival ben-
efit to patients undergoing T-replete HCT for AML.
KIR genotyping should be added to donor selection
criteria in addition to HLA typing, to identify donors
with B KIR haplotypes. Future investigators are aimed
at subsetting the KIR B haplotype for a more refined
donor selection strategy.CONCLUSION
NK cells have been of therapeutic interest for de-
cades as they kill tumor targets in vitro and in animal
models. Strategies to activate autologous NK cells
dominated the early literature but were found to lim-
ited efficacy. This was explained by the discovery of in-
hibitory receptors on NK cells that recognize ‘‘self’’
MHC molecules. Current strategies using allogeneic
NK cells are based on the premise that they will result
in a higher frequency of donor cells that will be reactive
against the recipient. The promising finding in AML
strongly support a role for the therapeutic use of NK
cells and offers the opportunity to further manipulate
these cells to exploit their full potential when
combined with allogeneic transplantation.ACKNOWLEDGMENTS
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